Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.

Autor: Back AR; Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA., Schleis SE; Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA., Smrkovski OA; Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA., Lee J; Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA., Smith AN; Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA., Phillips JC; Animal Emergency Critical Care and Referral Center, Knoxville, TN, USA.
Jazyk: angličtina
Zdroj: Veterinary and comparative oncology [Vet Comp Oncol] 2015 Dec; Vol. 13 (4), pp. 398-408. Date of Electronic Publication: 2013 Aug 05.
DOI: 10.1111/vco.12055
Abstrakt: Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7-858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42-274 days) and 38.6% experienced a partial response for a median of 49 days (range 7-858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49-858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7-274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17-974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma.
(© 2013 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje